There are now 174 cases of Candida auris infections in the United States, 17 more than the CDC reported last month.
December 19th, 2017December 15, 2017: Case Count Updated as of November 30, 2017
Candida auris is an emerging fungus that presents a serious global health threat. C. auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. auris for a long time and C. auris can persist on surfaces in healthcare environments. This can result in spread of C. auris between patients in healthcare facilities.
Most C. auris cases in the United States have been detected in the New York City area and New Jersey. Strains of C. auris in the United States have been linked to other parts of the world. U.S. C. auris cases are a result of inadvertent introduction into the United States from a patient who recently received healthcare in a country where C. auris has been reported or a result of local spread after such an introduction.
U.S. Map: Clinical cases of Candida auris reported by state, United States, as of November 30, 2017
Cases are categorized by the state where the specimen was collected. Most probable cases were identified when laboratories with current cases of C. auris reviewed past microbiology records for C. auris. Isolates were not available for confirmation. Early detection of C. auris is essential for containing its spread in healthcare facilities.
Table: Clinical cases of Candida auris reported by state, United States, as of November 30, 2017
| State | Number and type of clinical Candida auris cases reported | |
|---|---|---|
| Confirmed | Probable | |
| California | 1 | 0 |
| Connecticut | 1 | 0 |
| Florida | 2 | 0 |
| Illinois | 12 | 2 |
| Indiana | 1 | 0 |
| Maryland | 2 | 0 |
| Massachusetts | 6 | 0 |
| New Jersey | 38 | 23 |
| New York | 110 | 4 |
| Oklahoma | 1 | 0 |
| TOTAL | 174 | 29 |
Beyond the clinical case counts reported above, an additional 257 patients have been found to be colonized with C. auris by targeted screening in four states with clinical cases.
CDC encourages all U.S. laboratories that identify C. auris to notify their state or local public health authorities and CDC at candidaauris@cdc.gov. CDC is working closely with public health and healthcare partners to prevent and respond to C. auris infections. The CDC-sponsored Antibiotic Resistance Laboratory Network (ARLN) will help improve detection and response to C. auris nationwide.
Countries from which Candida auris cases have been reported, as of November 30, 2017
- Single cases of C. auris have been reported from Germany, Japan, Kuwait, and Norway.
- Multiple cases of C. auris have been reported from Canada, Colombia, India, Israel, Kenya, Oman, Pakistan, Panama, South Korea, South Africa, Spain, the United Kingdom, the United States (primarily from New York City Metropolitan Area and New Jersey) and Venezuela; in some of these countries, extensive transmission of C. auris has been documented in more than one hospital.
- U.S. cases of C. auris have been found in patients who had recent stays in healthcare facilities in India, Pakistan, South Africa and Venezuela, which also have documented transmission.
- Other countries not highlighted on this map may also have undetected or unreported C. auris cases.